A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician...
-
Upload
cadth-symposium -
Category
Technology
-
view
81 -
download
0
description
Transcript of A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician...
![Page 1: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/1.jpg)
Personalized medicines: Challenges and opportunities from bench to patients:
clinician researcher perspective
Janet Dancey, MD FRCPC
Ontario Institute for Cancer Research
NCIC Clinical Trials Group
![Page 2: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/2.jpg)
Personalized Medicine –One concept, a multitude of meanings and perspectives
Patient:I want my doctor to know about
my life, to understand me and my family and to help me reach
decisions that are best for me. I did not want to lose my hair on treatment so we found an option for me that would spare my hair.
Clinician:Which patient or disease
features will alter my approach to
prevention, screening, or treatment?
Scientist:Each patient’s cancer has genetic
changes and each patient has genomic variations that make
them unique. We are looking for those changes that will allow the right patient to receive the right
treatments matched to their genetic fingerprint.
Courtesy of E Eisenhauer 2013
Current status: A few successes – potential far from being realized
![Page 3: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/3.jpg)
Personalized medicine and cancer:A disease of the genome
Challenge in treating cancer:• Every tumour is different
• Every cancer patient is different
![Page 4: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/4.jpg)
International Cancer Genome Consortium
Projects as of April 2013
High rate of abnormalities (driver vs. passenger);Multiple clones that evolve under the selection
pressures including systemic therapySample type, quality and timing matter
Methods of analysis matter
![Page 5: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/5.jpg)
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
APC BRAF CTNNB1 EGFR KRAS NRAS PIK3CA PTEN RB1 STK11 TP53
Lung carcinoma (all subtypes)
Prostate adenocarcinoma
Breast carcinoma (all subtypes)
Colon adenocarcinoma
Pancreatic ductal adenocarcinoma
Ovarian carcinoma (all subtypes)
Hepatocellular carcinoma
Gastric adenocarcinoma
Renal cell carcinoma
Malignant melanoma
Surveys of mutation databases indicate that most mutations are found in many tumour types
Sanger Institute: http://www.sanger.ac.uk/cosmic, COSMIC v54 Release (Forbes et al., 2011).
![Page 6: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/6.jpg)
Gene Event Type Frequency, %
FGFR1 Amplification 20-25
FGFR2 Mutation 5
PIK3CA Mutation 9
PTEN Mutation deletion 18
CCND1 Amplification 8
CDKN2A Deletion/mutation 45
PDGFRA Amplification mutation
9
EGFR Amplification 10
MCL1 Amplification 10
BRAF Mutation 3
DDR2 Mutation 4
ERBB2 Amplification 2
Emerging “Druggable” Targets in NSCLC-Squamous Subtype
Lung Cancer Molecular Consortium Lung Adenocarcinomas
Kris MG, et al. ASCO 2011. CRA7506. Johnson BE, et al. IASLC WCLC 2011. Abstract O16.01
Hammerman P, et al. IASLC WCLC 2011. Abstract PRS.1
Many potential targets and biomarkers
MET AMP
Mutations found in 54% (280/516)
No mutationdetected KRAS
22%
EGFR17%
NRAS
Doublemutants 3%
AKT1
BRAF 2%
MEK1
HER2PIK3CA 2%
EML4-ALK7%
![Page 7: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/7.jpg)
• Need for rapid, accurate and comprehensive profiling of cancer relevant molecular abnormalities
• Need for repeated testing at critical management decision points
Genetic heterogeneity & emergence of resistance
![Page 8: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/8.jpg)
![Page 9: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/9.jpg)
CMAJ 2012. DOI:10.1503
![Page 10: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/10.jpg)
• Smith G, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003;327: 1459–61.
Personalized medicine: role of phase III trials
![Page 11: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/11.jpg)
Crizotinib trials and regulatory approval
• Two single arm trials of 255 patients with locally advanced or metastatic ALK-positive NSCLC
• Crizotinib 250 mg po twice daily
• No data available to show improvement in patient reported outcomes or survival
• 5 of 19 ALK-negative lung carcinoma patients responded; ORR = 26.3% (95% CI 9.1%, 51.2%); 2 additional patients had a single assessment of PR
• Approval of drug and diagnostic test
Study Patients (N) ORR % 95%CI Duration wks.
A 136 50 42%, 59% 42
B 119 61 52%, 70% 48
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202570s000ltr.pdf
1-yr OS: 74% 2-yr OS: 54%
![Page 12: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/12.jpg)
Personalized medicine: Integration of information
![Page 13: A2 -Personalized Medicines: Challenges and opportunities from bench to patients: clinician researcher perspective - Dancey - Salon C](https://reader034.fdocuments.in/reader034/viewer/2022051210/549c878db47959f3318b4776/html5/thumbnails/13.jpg)
The challenge is not just limited to increasing the knowledge about targeted therapies. A practical framework for clinicians and patients is needed.
Personalized medicine & health care
Dancey et al., Cell 2012